Novartis readies for FDA review of $1 billion CAR-T child cancer hope – Reuters
Reuters |
Novartis readies for FDA review of $1 billion CAR–T child cancer hope
Reuters Campana's 4-1BB is the key ingredient of the Swiss drugmaker's therapy, which involves T cells being extracted from patients, genetically re-engineered, and then unleashed to kill leukemia cells growing out of control. Of 68 desperately ill children … Novartis CAR-T safety in FDA spotlight – Pharmaphorum Novartis' CAR–T Therapy for Pediatric Leukemia to Face FDA Advisory Panel UPDATE 1-FDA panel to focus on safety of Novartis gene therapy … |
